Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21003170 | 0.89 | KDR (0.33) | KDRPNMT | |
| SCHEMBL4984720 | 0.79 | TSHR (0.33) | KDR | |
| SCHEMBL25678467 | 0.75 | CYP1A2 (0.36) | CD44KDRPNMT | |
| SCHEMBL29428699 | 0.74 | KDM4E (0.33) | CD44KDRPNMT | |
| SCHEMBL17298716 | 0.74 | KDM4E (0.33) | CD44KDRPNMT | |
| SCHEMBL19617837 | 0.74 | KDR (0.31) | KDR | |
| SCHEMBL19617838 | 0.74 | SIGMAR1 (0.30) | KDR | |
| Hydrochloric Acid SCHEMBL18010982 | 0.73 | KDM4E (0.32) | CD44KDRPNMT | |
| SCHEMBL21036380 | 0.70 | HTR2C (0.33) | CD44PNMT | |
| SCHEMBL4987970 | 0.70 | CD44 (0.38) | CD44KDRPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | CD44 3604/4885KDR 463/4885PNMT 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.